MDM2 and liposarcoma: Although preliminary results demonstrated no responses to MDM2 inhibitors among unselected patients,17-19 responses occurred in wild-type TP53 liposarcoma (MK-8242; response rate [RR], 11.1% [three of 27 patients]) or melanoma (AMG232; RR, 28.6% [six of 21 patients]).20,21